Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sets New 12-Month High – Here’s Why

Swedish Orphan Biovitrum (OTCMKTS:BIOVF)’s stock price reached a new 52-week high on Friday . The stock traded as high as $48.00 and last traded at $48.00, with a volume of 100 shares trading hands. The stock had previously closed at $48.00.

Wall Street Analysts Forecast Growth

BIOVF has been the topic of several recent research reports. Danske downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, February 19th. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. BNP Paribas Exane upgraded Swedish Orphan Biovitrum to an “outperform” rating in a report on Tuesday, February 10th. HC Wainwright began coverage on Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They issued a “buy” rating for the company. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Swedish Orphan Biovitrum presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

The company has a quick ratio of 0.47, a current ratio of 0.70 and a debt-to-equity ratio of 0.19. The business’s fifty day moving average is $43.76 and its 200-day moving average is $39.33. The stock has a market capitalization of $17.09 billion, a PE ratio of 160.00 and a beta of 0.36.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.07. The company had revenue of $755.76 million during the quarter, compared to analysts’ expectations of $749.76 million. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%. As a group, analysts anticipate that Swedish Orphan Biovitrum will post 2.22 EPS for the current fiscal year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.